多西他赛联合顺铂一线治疗晚期非小细胞肺癌  

First-line Chemotherapy of Docetaxel/Cisplatin for Advanced Non-small Cell Lung Cancer

作　　者：宋海平[1] 邱文生[2] 徐建华[1] 王颂平[1] 孙京栋 梁军[2] 

机构地区：[1]青岛市肿瘤医院内科,山东省青岛市266042 [2]青岛医学院附属医院肿瘤科

出　　处：《中国肿瘤临床》2007年第7期388-390,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:比较多西他赛及长春瑞滨联合顺铂一线治疗晚期非小细胞肺癌的疗效和不良反应。方法:67例晚期非小细胞肺癌患者随机分为2组。多西他赛组:多西他赛37.5mg/m2,d1,8,顺铂80mg/m2,分为3天,d1～3。长春瑞滨组:长春瑞滨25mg/m2,d1,8,顺铂用法同前。结果:多西他赛组有效率50%,1年生存率46.9%,2年生存率15.6%。长春瑞滨组有效率25.7%,1年生存率31.4%,2年生存率11.4%(P<0.05)。主要毒副作用为骨髓抑制、恶心、呕吐。结论:一线治疗晚期非小细胞肺癌多西他赛较长春瑞滨联合顺铂疗效高,生存期长。Objective： To compare the curative effect and safety of Doeetaxel with that of the Vinorelbine plus Cisplatin regimen for first-line therapy of advanced non-small cell lung cancer （NSCLC）. Methods： Sixty-seven patients with advanced NSCLC were divided into 2 groups, i.e., the Docetaxcel and Vinorelbine groups. In the Docetaxel group, the patients were given docetaxel 37.5mg/ m^2 on day 1 and day 8, and administration of eisplatin 80mg/m^2 was divided into 3 days, i.e., day 1 to day 3; In the Vinorelbine group, the patients were administered Vinorelbine 25 mg/m^2 on day 1 and day 8. The dose of cisplatin was as above. Results： The response rate of the Doeetaxel and Vinorelbine groups was 50% and 25.7%, respectively. The 1-year survival rate reached 46.9% in the Docetaxel group and 31.4% in the Vinorelbine group： and the 2-year survival rate in the 2 groups reached 15.6% and 11.4% （P〈0.05）, respectively. The major toxic effects included myelosuppression, nausea and vomiting. Conclusion： A reasonable efficacy and longer survival time are shown in the Doeetaxel group compared to the Vinorelbine plus cisplatin group in the treatment of advanced NSCLC.

关 键 词：非小细胞肺癌 化疗 多西他赛 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]